Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Myelodysplastic syndromes / neoplasms (MDS), drawn from the whole corpus: 44 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
5 medicines on record are linked to one of the types below rather than to Myelodysplastic syndromes / neoplasms (MDS) itself. Grouped by the type that holds them; each list opens that type's own page.
No drug has beaten azacitidine in higher-risk MDS.
TP53-mutant and complex-karyotype disease: median survival about a year even after transplant.
Clonal cytopenia of undetermined significance (CCUS): who to watch, who to treat.
Post-HMA failure has no standard.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 29 changes by month →When this page itself was last checked or edited.
Lower-risk MDS transfusion-dependent anaemia
Preparative regimen for allogeneic HSCT in AML/MDS with fludarabine
Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes.
Low- to intermediate-1-risk MDS with transfusion-dependent anaemia after ESA failure
IMerge: telomerase inhibitor achieves durable transfusion independence after ESA failure.